Meridian Bioscience: Q2 Earnings Insights
Meridian Bioscience (NASDAQ:VIVO) reported its Q2 earnings results on Friday, May 6, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For May 6, 2022
Companies Reporting Before The Bell
• Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion.
Meridian Bioscience’s Earnings: A Preview
Meridian Bioscience (NASDAQ:VIVO) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement.
Analysts estimate that Meridian Bioscience will report an earnings per share (EPS) of $0.47.
Meridian Acquires EUPROTEIN; Terms Not Disclosed
Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc.,
Cannabis Stock Gainers And Losers From April 22, 2022
GAINERS:
MariMed (OTC:MRMD) shares closed up 5.59% at $0.72
Cannabis Stock Gainers And Losers From April 7, 2022
GAINERS:
Origin Agritech (NASDAQ:SEED) shares closed up 15.34% at $8.42
Meridian Bioscience Launches Lyo-Ready qPCR Inhibitor Tolerant Blood-Specific Master Mixes For DNA & RNA Direct Detection
Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two new master mixes that detect DNA and RNA in crude blood
Marijuana Stock Movers For March 16, 2022
GAINERS:
MGC Pharmaceuticals (OTC:MGCLF) shares closed up 21.45% at $0.02
Magellan Diagnostics Resumes Distribution Of LeadCare II Test Kits
Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Magellan Diagnostics resumed manufacturing and distribution of their
HC Wainwright & Co. Maintains Buy on Meridian Bioscience, Raises Price Target to $30
HC Wainwright & Co. analyst Yi Chen maintains Meridian Bioscience (NASDAQ:VIVO) with a Buy and raises the price target from $28 to $30.